alpibectir   Click here for help

GtoPdb Ligand ID: 12957

Synonyms: BVL-GSK098
Compound class: Synthetic organic
Comment: Alpibectir is being developed by BioVersys AG and GlaxoSmithKline as an oral treatment for tuberculosis (TB) in combination with ethionamide or prothionamide. Alpibectir targets bacterial transcriptional regulators and potentiates the activity of drugs used in the treatment of TB, in particular drugs that are activatable via the EthA pathway. It is one of the spiroisoxazoline class of compounds claimed in patent WO2019034700A1 [1].
2D Structure
Click here for help

2D Structure

An image of the ligand's 2D structure. For small molecules with SMILES these are drawn using the NCI/CADD Chemical Identifier Resolver. Click on the image to access the chemical structure search tool with the ligand pre-loaded in the structure editor. For other types of ligands, e.g. longer nucleotides and peptides, a manually drawn representation of the molecule may be provided.

✖
Click here for structure editor
Physico-chemical Properties
Click here for help

Physico-chemical Properties

Calculated molecular properties are available for small molecules and natural products (not peptides). Properties were generated using the CDK toolkit. All properties were selected to enable the prediction of the Lipinski Rule-of-Five profile or ‘druglikeness’ for each ligand. For more info on each category see the help pages.

✖
Hydrogen bond acceptors 2
Hydrogen bond donors 0
Rotatable bonds 5
Topological polar surface area 41.9
Molecular weight 332.24
XLogP 3.13
No. Lipinski's rules broken 0
SMILES / InChI / InChIKey
Click here for help

SMILES / InChI / InChIKey

SMILES (Simplified Molecular Input Line Entry Specification) A specification for unambiguously describing the structure of chemical molecules using short ASCII strings. Canonical SMILES specify a unique representation of the 2D structure without chiral or isotopic specifications. Isomeric SMILES include chiral specification and isotopes.

Standard InChI (IUPAC International Chemical Identifier) and InChIKey InChI is a non-proprietary, standard, textual identifier for chemical substances designed to facilitate linking of information and database searching. An InChIKey is a simplified version of a full InChI, designed for easier web searching.

✖
Canonical SMILES C(CC(F)(F)F)C(=O)N1CCC2(CC1)CC(=NO2)C(F)(F)F
Isomeric SMILES C1CN(CCC12CC(=NO2)C(F)(F)F)C(=O)CCC(F)(F)F
InChI InChI=1S/C12H14F6N2O2/c13-11(14,15)2-1-9(21)20-5-3-10(4-6-20)7-8(19-22-10)12(16,17)18/h1-7H2
InChI Key ZEAVKHMQTZBUND-UHFFFAOYSA-N
No information available.
Summary of Clinical Use Click here for help
Alpibectir is being developed as a combination therapy with ethionamide to treat TB, with the aim of reducing the dose of ethionamide. It is hoped that this will reduce side-effects and help overcome drug-resistance. Alpibectir has completed a Phase 1 study (NCT04654143, last update January 2023) and has progressed to Phase 2 evaluation (NCT05473195, recruitment commenced).
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT05473195 A Phase 2 Trial to Evaluate the EBA, Safety and Tolerability of Eto Alone and in Combination With BVL-GSK098 Phase 2 Interventional TASK Applied Science
NCT04654143 Clinical Trial to Investigate the Safety, Tolerability and Pharmacokinetics of BVL-GSK098 in Healthy Volunteers Phase 1 Interventional BioVersys AG